ReviewJournal of pharmaceutical analysis2026
Metallic nanoparticles in precision medicine for gastrointestinal cancers: Diagnostic and therapeutic advances.
Review in Journal of pharmaceutical analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal cancers (GI) rank among the most common and lethal tumors. The traditional therapies face limitations in the early diagnosis, accurate targeting, and treatment effectiveness. Metallic nanoparticles (MNPs) such as Au, Ag, and iron oxide present various promising opportunities owing to their exceptional physicochemical properties including high surface area-to-volume ratios, tunable surface chemistry, and biological interactions. Therefore, understanding the function and application of MNPs in the treatment of specific cancers and advancing cancer diagnosis can provide valuable clinical insights. This review assesses the capabilities of MNPs in GI cancers, focusing on the drug delivery, imaging, photothermal therapy (PTT), and the enhancement of radiotherapy. The primary findings encompass using gold nanoparticles (AuNPs) for the targeted drug delivery, photothermal-induced tumor ablation, and radiosensitization in colorectal, pancreatic, and gastric cancers. AgNPs can not only enhance chemotherapy and photodynamic therapy (PDT) but also induce apoptosis. Iron oxide nanoparticles (IONPs) aid in magnetic drug targeting, enhance magnetic resonance imaging (MRI) contrast, and enable combined chemo-photothermal therapy. Metal-organic frameworks (MOFs) facilitate drug delivery, multimodal imaging, and combination treatments, including photodynamic and immunotherapy, for colorectal and pancreatic cancers. The review emphasizes the recent advancements in MNP-based theranostic platforms, showcasing their ability to enhance the early detection, overcome drug resistance, and boost the therapeutic index. The obstacles such as off-target effects, scalability and chronic toxicity are addressed, along with methods for enhancing MNP design and its clinical use. This review emphasizes the transformative possibilities of MNPs in tackling the worldwide challenge of GI cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.